Irish oncology care platform announces collaboration with NCCN

The Irish-founded oncology software company, ONCOassist, announces a new agreement with The National Comprehensive Cancer Network (NCCN). The collaboration will focus on integrating NCCN Content to create a digital tool that will help oncology professionals around the world stay up to date with relevant clinical content about cancer care. ONCOassist is a CE-approved decision support app for oncology professionals around the world. It is currently the only oncology app on the market with regulatory approval for use in a hospital setting. ONCOassist hosts tools and content specific to oncology and is used by more than 73,000 professionals across 150+ countries. It is estimated that 40 per cent of oncology healthcare professionals (HCPs) globally use ONCOassist. ONCOassist is revolutionizing the delivery of global cancer care and aiding in reaching the goal of improving the quality of patient care globally. NCCN is a not-for-profit alliance of 32 leading cancer centres devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. By joining forces, NCCN enables ONCOassist to make key decision support information available to their users around the world, advancing their mission of helping HCPs make more-informed oncology decisions. The new agreement will allow oncology clinicians to access relevant, up-to-date tools and content at their fingertips on the ONCOassist smartphone app. ONCOassist and NCCN are working together to bring their content to oncology clinicians around the world, irrespective of their resources. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the healthcare delivery system. According to Cancer Research UK, there are around 375,000 new cancer cases in the UK every year which is around 1,000 every day. Globally, 18,094,716 million cases of cancer were diagnosed in 2020 alone according to the World Cancer Research International Fund. With that in mind, DATA-CAN found that there was a significant drop in urgent referrals for early cancer diagnosis along with a noticeable reduction in chemotherapy attendance during the Covid-19 pandemic. This indicates that Covid-19 may have impacted and prevented patients from being diagnosed early on. ONCOassist aims to make life easier for both oncology professionals as well as patients themselves. When speaking about the agreement, co-founder and CEO of ONCOassist, Eoin O

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!